Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

BUY
$114.22 - $140.1 $5.79 Million - $7.1 Million
50,700 Added 1236.59%
54,800 $7.6 Million
Q4 2023

Feb 14, 2024

SELL
$75.49 - $124.16 $1.52 Million - $2.5 Million
-20,100 Reduced 83.06%
4,100 $508,000
Q3 2023

Nov 14, 2023

BUY
$86.06 - $137.93 $2.08 Million - $3.34 Million
24,200 New
24,200 $2.26 Million
Q4 2021

Feb 14, 2022

SELL
$129.87 - $162.82 $194,805 - $244,230
-1,500 Reduced 20.0%
6,000 $3.22 Million
Q3 2021

Nov 15, 2021

SELL
$106.71 - $143.18 $32,012 - $42,954
-300 Reduced 3.85%
7,500 $4.1 Million
Q2 2021

Aug 16, 2021

BUY
$80.99 - $107.93 $307,762 - $410,134
3,800 Added 95.0%
7,800 $3.33 Million
Q1 2021

May 17, 2021

SELL
$84.79 - $104.74 $2.52 Million - $3.11 Million
-29,700 Reduced 88.13%
4,000 $1.44 Million
Q4 2020

Feb 16, 2021

BUY
$78.0 - $104.5 $1.45 Million - $1.94 Million
18,600 Added 123.18%
33,700 $12.5 Million
Q3 2020

Nov 16, 2020

SELL
$95.51 - $112.95 $477,550 - $564,750
-5,000 Reduced 24.88%
15,100 $6.23 Million
Q2 2020

Aug 14, 2020

SELL
$62.68 - $105.34 $137,896 - $231,748
-2,200 Reduced 9.87%
20,100 $8.15 Million
Q1 2020

May 15, 2020

BUY
$47.79 - $75.63 $520,911 - $824,367
10,900 Added 95.61%
22,300 $6.01 Million
Q4 2019

Feb 14, 2020

BUY
$36.62 - $57.29 $124,507 - $194,786
3,400 Added 42.5%
11,400 $2.49 Million
Q3 2019

Nov 14, 2019

BUY
$35.53 - $43.8 $177,650 - $219,000
5,000 Added 166.67%
8,000 $1.19 Million
Q2 2019

Aug 14, 2019

BUY
$27.84 - $38.92 $83,520 - $116,760
3,000 New
3,000 $450,000
Q2 2018

Aug 14, 2018

SELL
$17.54 - $25.22 $945,406 - $1.36 Million
-53,900 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$13.06 - $18.54 $703,934 - $999,306
53,900 New
53,900 $4 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $30.7B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.